Clinical Trial Update: NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma [Phase 1]

View source ↗

Summary

A Phase 1 study from Dana-Farber Cancer Institute evaluating NeoVax plus CDX-301 with nivolumab or pembrolizumab in melanoma; the trial is currently active but …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CDX-301
• NeoVax
• Pembrolizumab (pembrolizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Melanoma, Metastatic Melanoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING